评估银屑病和特应性皮炎的治疗相关免疫生物标志物：走向皮肤科的个体化医学。
Assessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology.
机构信息
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA; Medical Scientist Training Program, Yale School of Medicine, New Haven, Connecticut, USA.
Yale College, Yale University, New Haven, Connecticut, USA.
出版信息
J Invest Dermatol. 2023 Aug;143(8):1412-1422. doi: 10.1016/j.jid.2023.04.005. Epub 2023 Jun 20.
Abstract
Immunologically targeted therapies have revolutionized the treatment of inflammatory dermatoses, including atopic dermatitis and psoriasis. Although immunologic biomarkers hold great promise for personalized classification of skin disease and tailored therapy selection, there are no approved or widely used approaches for this in dermatology. This review summarizes the translational immunologic approaches to measuring treatment-relevant biomarkers in inflammatory skin conditions. Tape strip profiling, microneedle-based biomarker patches, molecular profiling from epidermal curettage, RNA in situ hybridization tissue staining, and single-cell RNA sequencing have been described. We discuss the advantages and limitations of each and open questions for the future of personalized medicine in inflammatory skin disease.
摘要
免疫靶向治疗已经彻底改变了炎症性皮肤病的治疗方法，包括特应性皮炎和银屑病。虽然免疫生物标志物为皮肤病的个性化分类和针对性治疗选择提供了巨大的希望，但在皮肤科领域，还没有经过批准或广泛使用的方法。本综述总结了用于测量炎症性皮肤疾病中治疗相关生物标志物的转化免疫方法。已经描述了胶带条分析、基于微针的生物标志物贴片、表皮刮除术的分子分析、RNA 原位杂交组织染色和单细胞 RNA 测序。我们讨论了每种方法的优缺点以及炎症性皮肤病个性化医学的未来的开放性问题。
相似文献
1
Assessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology.
J Invest Dermatol. 2023 Aug;143(8):1412-1422. doi: 10.1016/j.jid.2023.04.005. Epub 2023 Jun 20.
2
Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases.
APMIS. 2019 May;127(5):386-424. doi: 10.1111/apm.12934.
3
Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis.
Int J Mol Sci. 2024 Jan 15;25(2):1042. doi: 10.3390/ijms25021042.
4
Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis.
J Allergy Clin Immunol. 2021 Jan;147(1):199-212. doi: 10.1016/j.jaci.2020.05.048. Epub 2020 Jul 21.
5
Atopic dermatitis endotypes: knowledge for personalized medicine.
Curr Opin Allergy Clin Immunol. 2022 Jun 1;22(3):153-159. doi: 10.1097/ACI.0000000000000820. Epub 2022 Feb 11.
6
Dermatologic Disease-Directed Targeted Therapy (DT): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions-Precision Dermatology.
Dermatol Ther (Heidelb). 2022 Oct;12(10):2249-2271. doi: 10.1007/s13555-022-00801-2. Epub 2022 Sep 19.
7
Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Actas Dermosifiliogr (Engl Ed). 2021 July/August;112(7):586-600. doi: 10.1016/j.adengl.2021.05.008. Epub 2021 May 12.
8
Mapping ethical and social aspects of biomarker research and its application in atopic dermatitis and psoriasis: a systematic review of reason.
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1201-1213. doi: 10.1111/jdv.18128. Epub 2022 Apr 20.
9
Therapeutic Synergy, Neutrality, and Antagonism: Combination Treatment in Dermatology.
J Drugs Dermatol. 2016 Oct 1;15(10):1203-1207.
10
In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery.
Basic Clin Pharmacol Toxicol. 2006 Aug;99(2):104-15. doi: 10.1111/j.1742-7843.2006.pto_298.x.
引用本文的文献
1
Precision medicine and Treat-to-Target approach in atopic dermatitis: enhancing personalized care and outcomes.
An Bras Dermatol. 2025 Jun 18;100(4):501135. doi: 10.1016/j.abd.2025.501135.
2
Genetic profiling and precision skin care: a review.
Front Genet. 2025 Jun 3;16:1559510. doi: 10.3389/fgene.2025.1559510. eCollection 2025.
3
Diagnostic and Therapeutic Challenges in Psoriasis-Atopic Dermatitis Overlap: A Retrospective Observational Cohort Study.
Diagnostics (Basel). 2025 May 29;15(11):1381. doi: 10.3390/diagnostics15111381.
4
JAK Inhibitors and Inflammatory Nail Disorders: A Systematic Review of Clinical Outcomes and Therapeutic Potential.
Am J Clin Dermatol. 2025 Apr 23. doi: 10.1007/s40257-025-00946-8.
5
Advancements in pharmacological interventions for atopic dermatitis current strategies and future directions.
Inflammopharmacology. 2025 Mar;33(3):1221-1236. doi: 10.1007/s10787-025-01659-4. Epub 2025 Feb 15.
6
Topical Anti-Inflammatory Effects of Quercetin Glycosides on Atopic Dermatitis-Like Lesions: Influence of the Glycone Type on Efficacy and Skin Absorption.
Inflammation. 2025 Jan 14. doi: 10.1007/s10753-025-02236-1.
7
Skin Predictive Biomarkers for the Development of Atopic Dermatitis and Food Allergy in Infants.
Allergy Asthma Immunol Res. 2024 Jul;16(4):323-337. doi: 10.4168/aair.2024.16.4.323.
8
Novel Quinazoline Derivative Induces Differentiation of Keratinocytes and Enhances Skin Barrier Functions against Th2 Cytokine-Mediated Signaling.
Molecules. 2023 Aug 18;28(16):6119. doi: 10.3390/molecules28166119.
本文引用的文献
1
mRNA Staining Distinguishes Palmoplantar Psoriasis from Hyperkeratotic Palmoplantar Eczema in Diagnostic Skin Biopsies.
JID Innov. 2023 Feb 10;3(4):100189. doi: 10.1016/j.xjidi.2023.100189. eCollection 2023 Jul.
2
Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
J Clin Med. 2023 Mar 11;12(6):2189. doi: 10.3390/jcm12062189.
3
mRNAs in skin surface lipids unveiled atopic dermatitis at 1 month.
J Eur Acad Dermatol Venereol. 2023 Jul;37(7):1385-1395. doi: 10.1111/jdv.19017. Epub 2023 Mar 21.
4
Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis.
J Am Acad Dermatol. 2023 May;88(5):1094-1100. doi: 10.1016/j.jaad.2022.12.052. Epub 2023 Feb 11.
5
Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab.
Br J Dermatol. 2023 Apr 20;188(5):649-660. doi: 10.1093/bjd/ljad032.
6
Defining Patient-Level Molecular Heterogeneity in Psoriasis Vulgaris Based on Single-Cell Transcriptomics.
Front Immunol. 2022 Jul 26;13:842651. doi: 10.3389/fimmu.2022.842651. eCollection 2022.
7
Biomarkers of systemic treatment response in people with psoriasis: a scoping review.
Br J Dermatol. 2022 Oct;187(4):494-506. doi: 10.1111/bjd.21677. Epub 2022 Jul 20.
8
Single-cell analysis implicates T17-to-T2 cell plasticity in the pathogenesis of palmoplantar pustulosis.
J Allergy Clin Immunol. 2022 Oct;150(4):882-893. doi: 10.1016/j.jaci.2022.04.027. Epub 2022 May 12.
9
Minimally Invasive Skin Transcriptome Extraction Using a Dermal Biomarker Patch.
Dermatol Ther (Heidelb). 2022 Jun;12(6):1313-1323. doi: 10.1007/s13555-022-00733-x. Epub 2022 Apr 30.
10
Biomarkers of disease progression in people with psoriasis: a scoping review.
Br J Dermatol. 2022 Oct;187(4):481-493. doi: 10.1111/bjd.21627. Epub 2022 Jul 11.
Zotero 插件